Sana Biotechnology, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven D. Harr
- Full Time Employees
- 194
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 188 East Blaine Street Seattle WA United States of America 98102
- IPO Date
- Feb 4, 2021
- CIK
- 0001770121
- Website
- sana.com
- Similar Companies
- Business
- Sana Biotechnology, Inc. develops engineered cell therapies aimed at repairing or controlling genes in cells and replacing missing or damaged cells to treat diseases at their root causes. Its primary products and services include engineered cell medicines leveraging in vivo delivery platforms using lipid nanoparticles and adeno-associated viruses; ex vivo cell engineering platforms for modifying therapeutic cells outside the body; and a hypoimmune platform designed to enable donor cells to evade immune rejection, broadening allogeneic cell therapy applications. The company’s pipeline features candidates targeting oncology, diabetes (notably the SC451 program for type 1 diabetes), autoimmune diseases, and CNS disorders, with prominent programs like the in vivo CAR T platform and SC291 for lupus. Founded in 2018 and headquartered in Seattle, Washington, Sana operates additional sites in Cambridge, Massachusetts, South San Francisco, and Rochester. Recent strategic shifts include suspending less successful allogeneic CAR T programs to reallocate resources toward high-potential assets such as SC451 and the in vivo CAR T platform, reflecting a focused optimization of its therapeutic pipeline. Additionally, Sana completed a $75 million public offering in 2025 to bolster its financial position, while its operational emphasis remains on advancing cell engineering technologies through extensive research and development. Its recent financial results demonstrate progress by surpassing earnings expectations with improved cost management despite ongoing investment in R&D, positioning the company toward potential future profitability and growth. Sana continues to engage key investors through presentations at major healthcare conferences, highlighting its leadership in engineered cell medicines and commitment to transforming treatment options for complex diseases.
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Sana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $8.00
Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript
Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Sana Biotechnology to Present at March 2026 Investor Conferences
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
Sana Biotechnology: A Small, Speculative Play
Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Rating of “Moderate Buy” from Analysts
Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know
Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet
Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips
Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript